GRAL grail.com Earnings per share growth in current year

Official company branding of GRAIL, Inc. (GRAL)

Integrating tests into corporate insurance ensures clinic loyalty, which illustrates the percentage growth rate of GRAIL, Inc. (GRAL) earnings per share YoY. The value of 13.80 shows the latest reading of this trend. Success is based on unique Galleri patents and strict FDA control. Growth is driven by the commercial implementation of blood analysis and potential recognition by Medicare as a diagnostic standard.

Earnings per share growth in current year: GRAIL Corp (GRAL) for 06/29/2024 - 11/12/2026

Analytical breakdowns and data insights for company GRAIL, Inc. (GRAL)

- market value and analyst target forecast:
Stock Price GRAIL Inc|GRAL - Price Target Chart
- market capitalization data:
Market Value GRAIL Bio|GRAL - Real Price to Acquire Entire Company
- book capitalization indicators:
Net Asset Value per Share GRAIL|GRAL - Company Book Value|Market Capitalization to Book Value grail.com|GRAL - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient GRAIL, Inc.|GRAL - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient grail.com|GRAL - Company Aggregate Debts|Debt to Net Assets GRAIL Bio|GRAL - Company Long-Term Debt|Company Short-Term Loans and Borrowings GRAIL|Quick Ratio grail.com
- company profitability and valuation multiples indicators:
GRAL - Net Profit|Company Profit Forecast GRAIL, Inc.|GRAL - Price to Earnings Ratio|Future Price to Earnings GRAIL Bio|GRAL - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation GRAIL Bio|GRAL - Operating profit EBITDA|Net earnings per share for the last four quarters GRAIL|GRAL - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months grail.com|GRAL - Earnings growth in current year|Expected earnings per share growth for next year GRAIL, Inc.
Fundamental valuation:GRAL (GRAIL Inc)
Mass-produced product of GRAIL

For the multi-cancer screening leader GRAIL, Inc. (GRAL), the current YoY EPS growth rate serves as an indicator of the efficiency of monetizing unique clinical data under strict regulatory control. This metric measures the annual dynamics of earnings per share, allowing for an assessment of the business's ability to scale profitability faster than inflationary costs, which determines the company's long-term investment attractiveness.

Main competitors

Caris Life Sciences Inc (CAI) - Earnings growth in current year|Earnings per share growth in current year Guardant360|Earnings per share growth in current year VCYT|Net earnings per share growth this year CELC (Celcuity Inc.)|MYGN - Earnings per share growth rate in current year|Earnings per share growth in current year Castle Biosciences, Inc. CSTL|Expected net earnings per share growth this year Burning Rock Biotech Limited (BNR)|VolitionRx Ltd - Earnings growth in current year|Expected net earnings per share growth this year Biodesix Corporation BDSX|Precipio, Inc. (PRPO) - Earnings per share growth in current year|CHEK - Expected net earnings per share growth this year|MYNZ (Mainz Biomed) - Earnings growth in current year|OCX - Net earnings per share change in current year